ACT Genomics officially launched collaboration with ASLAN Pharmaceuticals as the biomarker exploration partner for Varlitinib in Australia, Hong Kong, Hungary, Japan, Malaysia, Poland, Singapore, South Korea, Spain, Taiwan, Thailand and United States. ASLAN began a global pivotal trial to investigate Varlitinib as a treatment for gastric cancer, biliary tract cancer, and metastatic colorectal cancer. Currently, there is no approved therapies for biliary tract cancer. ASLAN Pharmaceuticals is a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumor types.
More on ASLAN: http://aslanpharma.com/